Meta Pixel

News and Announcements

Crowd Mobile Reports Record Fourth Quarter with $11.6m in Revenue & $3.3 EBITDA

  • Published July 18, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Crowd Mobile Limited (ASX: CM8) has recently announced the Fourth Quarter results for the three months ended 30 June 2017. Record quarterly revenue has supported the company’s strong FY17 performance.

KEY TAKEAWAYS: 

  • Revenue of $11.6 million
  • Underlying EBITDA of $3.3 million
  • Strong Positive Underlying Operating cash flow of $2.2 million
  • Net Debt of $2.7 million

Crowd Mobile’s Chief Executive Officer, Domenic Carosa: “Crowd Mobile is delighted to finish a successful 2017 financial year with a record fourth quarter. Over the quarter our Revenue at $11.6 million, Underlying EBITDA of $3.3 million and Underlying Operating Cash Flow have grown strongly from the prior quarter.

Over the year our Q&A business has enjoyed another stellar year, growing 58% in message volumes from the prior year, which continues a very consistent cumulative growth rate since going public. Crowd Mobile’s Net Debt has been reduced by more than 80% in FY17 and the Company is committed to transitioning to a net cash position in FY18.

Crowd Mobile will continue to focus on organically growing its core businesses while creating new revenue streams from our Digital Influencer business (Crowd Media) and we look forward to updating shareholders with material developments as they occur.”

More Information

Request Offer

Capital Insights
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.

Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation

Capital Insights
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula

Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.

Join over 45,000+ sophisticated investors

Join Now